Key Takeaways From FDA's Latest Social Media Warnings
By Dominick DiSabatino, Cortney Inman and Julian Klein · December 3, 2024, 6:23 PM EST
On Oct. 31, the U.S. Food and Drug Administration's Office of Prescription Drug Promotion posted an untitled letter taking issue with Merz Pharmaceuticals GmbH's social media promotion of Xeomin, an injection...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login